Sanofi (SNY): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Sanofi ( SNY) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.2%. By the end of trading, Sanofi fell $0.83 (-1.6%) to $52.00 on heavy volume. Throughout the day, 2,372,910 shares of Sanofi exchanged hands as compared to its average daily volume of 1,442,300 shares. The stock ranged in price between $51.71-$52.34 after having opened the day at $52.18 as compared to the previous trading day's close of $52.83. Other companies within the Drugs industry that declined today were: Mast Therapeutics ( MSTX), down 38.9%, Aastrom Biosciences ( ASTM), down 11.5%, Pernix Therapeutics Holdings ( PTX), down 9.8% and Orexigen Therapeutics ( OREX), down 9.5%.

Sanofi researches, develops, manufactures, and markets healthcare products worldwide. The company operates through Pharmaceuticals, Human Vaccines, and Animal Health segments. Sanofi has a market cap of $140.2 billion and is part of the health care sector. The company has a P/E ratio of 28.3, above the S&P 500 P/E ratio of 17.7. Shares are up 11.1% year to date as of the close of trading on Friday. Currently there are 2 analysts that rate Sanofi a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front, Biostar Pharmaceuticals ( BSPM), up 38.1%, XOMA ( XOMA), up 22.2%, Prana Biotechnology ( PRAN), up 16.5% and Galena Biopharma ( GALE), up 12.2% , were all gainers within the drugs industry with Biogen Idec ( BIIB) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

Citi Will Refund $335 Million in Card Charges: LIVE MARKETS BLOG

Citi Will Refund $335 Million in Card Charges: LIVE MARKETS BLOG

Generic Drug Makers Hurt By Latest Federal Government Budget

Generic Drug Makers Hurt By Latest Federal Government Budget

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Investors Are Trying to Figure Out the 'Powell Put'

Investors Are Trying to Figure Out the 'Powell Put'

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done